Patent US4788202A successfully refreshed from Google Patents.
US4788202A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sulphonamide derivatives as α2 -adrenoceptor antagonists
Assignee: John Wyeth and Brother Ltd
•
Filing: 1987-07-09
•
Granted: 1988-11-29
•
Expires: 2007-07-09
Abstract
Abstract The invention concerns sulphonamides of general formula ##STR1## and their pharmaceutically acceptable acid addition salts. In formula (I), R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or aryl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl). The compounds possess α 2 -adrenoceptor antagonistic activity in warm blooded animals.
Inventors
- 👤 Terence J. Ward
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 18:34
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/12; C07D471/14; A; A61; A61P; A61P25/00; A61P25/02; C07D491/00; C07D491/12; C07D491/14; C07D495/00; C07D495/12; C07D495/14
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
131 words
A compound selected from the group consisting of a sulphonamide of the formula (I) ##STR11## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or pheny substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 2
Dependent Claim
131 words
A compound selected from the group consisting of a sulphonamide of the formula (I) ##STR11## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or pheny substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 3
Dependent Claim
11 words
A compound as claimed in claim 1 wherein A is ethylene.
Claim 4
Dependent Claim
18 words
A compound according to claim 1 which is N-[(2β, 12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamidoethyl)methanesulphonamide or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
29 words
A compound according to claim 1 which is N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl]-N-(-2-ethanesulphonamidoethyl)ethanesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-indolo[2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamido)ethyl)ethanesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-indolo[2,3-a]quinolizin-2-yl]-N(-2-ethanesulphonamidoethyl)ethanesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo [2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamidoethyl) benzenesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl]-N-(2-methanesulphonamidoethyl)-p-methylbenzenesulphonamide, or N-[(2β,12bα)-1,3,4,6,7,12b-hexahydro-2H-benzo[b]thieno[2,3-a]-quinolizin-2-yl]-N-(2-methanesulphonamidoethyl)methanesulphonamide or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim
155 words
A pharmaceutical composition having α 2 -adrenoceptor antagonistic activity comprising an amount effective to antagonise α 2 -adrenoceptors of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR12## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl) and a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
155 words
A pharmaceutical composition having α 2 -adrenoceptor antagonistic activity comprising an amount effective to antagonise α 2 -adrenoceptors of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR12## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl) and a pharmaceutically acceptable carrier.
Claim 8
Independent Claim
152 words
A method of antagonising α 2 -adrenoceptors in warm blooded animals which comprises administering to the animal an effective amount of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR13## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 9
Independent Claim
152 words
A method of antagonising α 2 -adrenoceptors in warm blooded animals which comprises administering to the animal an effective amount of a compound selected from the group consisting of a sulphonamide of the formula (I) ##STR13## and a pharmaceutically acceptable acid addition salt thereof, wherein R represents hydrogen or lower alkyl, R 1 and R 2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R 3 and R 4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or phenyl or phenyl substituted by one or more substituents selected from halogen, lower alkoxy, lower alkyl, alkylenedioxy, nitro, amino, lower acylamino, lower alkylamino, diloweralkylamino and trifluoromethyl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR 5 (where R 5 is hydrogen or lower alkyl).
Claim 10
Dependent Claim
82 words
A compound of formula (XIII) ##STR14## or an acid addition salt thereof, wherein R, R 1 , R 2 , X and A are as defined in claim 1 and Z 1 and Z 2 are both hydrogen or Z 1 is hydrogen and Z 2 is SO 2 R 4 (where R 4 is as defined in claim 1) or Z 1 is SO 2 R 3 (where R 3 is as defined in claim 1) and Z 2 is hydrogen.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-29 | 1992-05-30 | 1992-11-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-29 | 1996-05-30 | 1996-11-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-29 | 2000-05-30 | 2000-11-29 | $7700.00 | Window Closed / Lapsed |